At a glance
- Originator Oculon
- Class Antihyperlipidaemics; Small molecules; Vitamins
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cataracts
Most Recent Events
- 16 May 2006 Discontinued - Phase-III for Cataracts in USA (Ophthalmic)
- 20 Feb 1997 Phase-III clinical trials for Cataracts in USA (Ophthalmic)